Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P01275 (
glucagon
)
26,492
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
In some cases patients with Type 2 (non-insulin-dependent) diabetes mellitus fail to respond to treatment with oral hypoglycaemic agents. These patients may respond in the same way as Type 1 (insulin-dependent) diabetic patients. Cellular immune
aggression
(defined as the capacity of peripheral mononuclear cells to inhibit stimulated insulin secretion by dispersed rat islet cells), insulin autoantibodies, C-peptide response and HLA antigens were determined in 31 Type 2 diabetic patients with secondary failure to oral hypoglycaemic agents and in 22 control subjects. Nine (29.03%) of the 31 Type 2 diabetic patients showed positive cellular immune
aggression
(2 SD below control group) and 22 (70.97%) presented no cellular immune
aggression
. There was a relationship between positive cellular immune
aggression
and each of the following parameters: age, body mass index and microangiopathy. No correlation was found between positive cellular immune
aggression
and glycaemia, HbA1, blood lipids or atherosclerosis. Patients with positive cellular immune
aggression
showed a significantly lower
glucagon
-stimulated C-peptide response vs those with no cellular immune
aggression
. Within a sub-group of patients who had never been treated with insulin, insulin autoantibodies were present in four of six patients with positive cellular immune
aggression
. DR2 antigen was found with decreased frequency in patients whereas no DR3/DR4 heterozygotes were observed. Our data support the hypothesis that a group of Type 2 diabetic patients with secondary failure to oral hypoglycaemic agents presented autoimmunity towards pancreatic Beta cells.
...
PMID:Cellular and humoural autoimmunity markers in type 2 (non-insulin-dependent) diabetic patients with secondary drug failure. 147 68
Major burns produce a variety of metabolic and nutritional consequences. The patient's metabolic rate is often doubled, and caloric demands of 3000 to 5000 calories per day are not uncommon. There are marked hormonal changes characterized by an increase in secretion of catecholamine and
glucagon
and a reversal of the normal insulin-to-
glucagon
ratio. Serum glucose increases primarily through hepatic gluconeogenesis to meet the increased demands of the burn wound and of the increased metabolic rate. Lipids may be available but they are an inefficient source of calories. Skeletal and visceral proteins are mobilized to meet the increased nutritional demands. The overall result is a severely catabolic patient in negative nitrogen balance, with decreased immunologic function and all of the wound-healing problems associated with protein and calorie malnutrition.
Aggressive
nutritional support (using enteral feeding whenever possible) is essential. Supplemental feedings should be started on all patients unable to reach their recommended calorie and protein requirements through regular oral diet. An increase in protein intake (calorie-to-nitrogen ratio of 100:1) may be beneficial. By establishing nutritional goals and monitoring daily weight, calorie count, protein intake, and biochemical parameters, the physician can significantly improve the chances of survival of even the most seriously injured patients.
...
PMID:Nutritional and metabolic consequences of thermal injury. 308 66
Aggressive behavior
, motor activity and defecation were examined simultaneously in wild male mice following daily growth hormone (GH) administration. GH was found to increase isolation-induced
aggression
by increasing fighting duration and decreasing latency to fight. There was no influence on non-aggressive motor activity nor on the defecation rate, a presumed parameter of emotionality. The results provide evidence of behavioral properties of GH. The mechanism of this action is discussed in terms of a possible direct central action of GH, not mediated by
glucagon
, insulin, secretin and gastrin.
...
PMID:Growth hormone and isolation-induced aggression in wild male mice. 719 89
Calcium channel antagonists are used primarily for the treatment of hypertension and tachyarrhythmias. Overdose of calcium channel antagonists can be lethal. Calcium channel antagonists act at the L-type calcium channels primarily in cardiac and vascular smooth muscle preventing calcium influx into cells with resultant decreases in vascular tone and cardiac inotropy and chronotropy. The L-type calcium channel is a complex structure and is thus affected by a large number of structurally diverse antagonists. In the setting of overdose, patients may experience vasodilatation and bradycardia leading to a shock state. Patients may also be hyperglycaemic and acidotic due to the blockade of L-type calcium channels in the pancreatic islet cells that affect insulin secretion.
Aggressive
therapy is warranted in the setting of toxicity. Gut decontamination with charcoal, or whole bowel irrigation or multiple-dose charcoal in the setting of extended-release products is indicated. Specific antidotes include calcium salts,
glucagon
and insulin. Calcium salts may be given in bolus doses or may be employed as a continuous infusion. Care should be exercised to avoid the administration of calcium in the setting of concomitant digoxin toxicity. Insulin administration has been used effectively to increase cardiac inotropy and survival. The likely mechanism involves a shift to carbohydrate metabolism in the setting of decreased availability of carbohydrates due to decreased insulin secretion secondary to blockade of calcium channels in pancreatic islet cells. Glucose should be administered as well to maintain euglycaemia. Supportive care including the use of phosphodiesterase inhibitors, adrenergic agents, cardiac pacing, balloon pump or extracorporeal bypass is frequently indicated if antidotal therapy is not effective. Careful evaluation of asymptomatic patients, including and electrocardiogram and a period of observation, is indicated. Patients ingesting a nonsustained-release product should be observed in a monitored setting for 12 hours, while those who ingest a sustained-release preparation should be observed for no less than 24 hours. Charcoal should be given to the asymptomatic patient with a history of calcium channel antagonist overdose.
...
PMID:Management of calcium channel antagonist overdose. 1253 24
Small cell carcinomas of the uterine cervix are rare tumors with an
aggressive behavior
. Although these tumors can exhibit neuroendocrine differentiation, the criteria for neuroendocrine differentiation are subjective and not well defined. In this study, the authors tentatively defined small cell neuroendocrine carcinoma (SCNEC) as a tumor composed of small cells with at least two of the following: argyrophilic cytoplasm, chromogranin A immunoreactivity, and synaptophysin immunoreactivity. We found 10 cases fulfilling these requirements. Five of the 10 tumors were composed mainly of small ("oat") cells and 5 of mainly larger "intermediate" cells. The majority of both subtypes showed an insular pattern. Three of the 10 SCNECs were pure, whereas the other seven were mixed with adenocarcinoma and/or squamous cell carcinoma or cervical intraepithelial neoplasia. In addition to the definitional markers noted earlier, the tumors were immunoreactive for serotonin (6 cases), somatostatin, gastrin,
glucagon
, and pancreatic polypeptide. No tumors were immunoreactive for cytokeratin 20. Human papillomavirus (HPV)-18 was detected in all of the pure tumors and both the SCNEC and adenocarcinomatous components in four of the mixed tumors. No other types of HPV were detected. The tumors showed a relatively low frequency of loss of heterozygosity for representative tumor suppressor gene sites; p53 mutations were found in only one case.
...
PMID:Small cell neuroendocrine carcinomas of the uterine cervix: a histological, immunohistochemical, and molecular genetic study. 1538 6
The aim of this study was to investigate the ultrastructural appearance of pancreatic adenocarcinoma combined with
glucagon
and gastrin/cholecystokinin (CCK) expression. The authors investigated the ultrastructure and the immunocytochemistry of 12 human pancreatic cancer specimens and used 3 chronic pancreatitis samples and 6 adjacent histological normal pancreatic tissues (away from the tumor) as controls. The ultrastructural study revealed that chronic pancreatitis tissues were characterized by alterations of the secretory cells. The enzymic and secretory changes were confirmed by electron immunogold results.
Glucagon
appeared to be located not only in islet alpha cells but also in intermediate alpha acinar cells. The changes were more significant in adenocarcinoma cases. Abnormality in the immunoreaction of the peptides was indicated not only in the tumor area but also in the islets near the cancer. Cells immunoreactive with antibodies were found in all 12 adenocarcinoma cases. Abnormal co-location of both hormones in the same type of endocrine cell was also found. Moderately to poorly differentiated adenocarcinomas were poorly granulated compared with differentiated tumors. Increased and ectopic gastrin/CCK expression was correlated with pancreatic adenocarcinomas exhibiting poor histological grade and neoplastic endocrine cells, providing a potential marker for pancreatic adenocarcinomas with
aggressive behavior
.
...
PMID:Immunoelectron study of pancreatic carcinomas using antibodies to gastrointestinal hormones. 1778 31
Mice selected for
aggression
and coping (long attack latency (LAL), reactive coping strategy; short attack latency (SAL), pro-active coping strategy) are a useful model for studying the physiological background of animal personalities. These mice also show a differential stress responsiveness, especially in terms of hypothalamic-pituitary-adrenal axis reactivity, to various challenges. Since the stress response can increase the production of reactive oxygen species, we predicted that the basic oxidative status of the lines could differ. We found that LAL showed higher serum antioxidant capacity (
OXY
) than SAL, while no differences emerged for reactive oxygen metabolites (ROMs) or the balance between ROMs and
OXY
, reflecting oxidative stress. Moreover, the lines showed inverse relationships between ROMs or
OXY
and body mass corrected for age. The results indicate that variation in oxidative status is heritable and linked to personality. This suggests that different animal personalities may be accompanied by differences in oxidative status, which may predict differences in longevity.
...
PMID:Aggressive and non-aggressive personalities differ in oxidative status in selected lines of mice (Mus musculus). 1804 11
Non-specific
aggression
to endocrine alpha and beta cells as well as exocrine pancreas has been suggested in fulminant type 1 diabetes (FT1DM), while its effect on
glucagon
secretion and exocrine function is unknown. Here, we report a FT1DM case with exocrine pancreatic insufficiency and enhanced
glucagon
response to meal ingestion.
...
PMID:A case of fulminant type 1 diabetes mellitus with exocrine pancreatic insufficiency and enhanced glucagon response to meal ingestion. 1878 50
The rapid and often relentless progression of type 2 diabetes suggests that high-risk patients should be provided with an equally aggressive strategy to protect their remaining beta-cell function and endogenous insulin secretion. Management of patients with prediabetes should incorporate both lifestyle and pharmacologic intervention. Although no specific recommendations are published for the management of prediabetes, one can assume that preservation of pancreatic beta-cell function, improvement in peripheral insulin resistance and pancreatic insulin secretion, reducing pancreatic alpha-cell secretion of
glucagon
, preventing long- and short-term diabetes-related complications, and assisting patients to loose weight are beneficial.
Aggressive
, timely, and physiologic management of prediabetes should be advocated.
...
PMID:Preventing type 2 diabetes. 1892 23
Propafenone is an anti-arrhythmic drug used in the management of supraventricular and ventricular arrhythmias. It is metabolised through cytochrome P450 2D6 pathways; the major metabolites possess anti-arrhythmic activity. The cytochrome P450 CYP2D6 is coded by more than 70 alleles resulting in great genetic polymorphism of CYP2D6 isoenzymes, and up to 7% of Caucasian population are poor metabolisers. This case report describes a patient with severe overdose of propafenone who presented with coma, seizures and cardiotoxicity. The patient was managed with intravenous
glucagon
, hypertonic sodium bicarbonate, hypertonic saline and inotropic support. The propafenone and its 5-hydroxypropafenone (5-OHP) metabolite were measured by high-performance liquid chromatography with ultraviolet detection (no assay was available at the time to measure N-despropyl propafenone concentrations). Toxicological screen showed propafenone concentrations at a maximum of 1.26 mg/L at 9-10 h post-presentation, falling to 0.25 mg/L at 27-28 h post-presentation. No propafenone metabolite 5-OHP was detected in any sample analysed. No antidepressant or analgesic drugs were detected in toxicological screen. Propafenone overdose has been reported to be associated with features of severe cardiovascular and CNS toxicity.
Aggressive
treatment, meticulous monitoring and supportive care was associated with a good outcome in this case.
...
PMID:Propafenone poisoning--a case report with plasma propafenone concentrations. 2037 66
1
2
Next >>